In December 2020, the SARS-CoV-2 vaccine (BNT162b2, Comirnaty®, BioNTech/Pfizer) was approved by the European Medicines Agency. Recently, BNT162b2 was started to be administered to high-risk populations for COVID-19 in Germany.1 We here report the first case of an elderly patient who developed erythema multiforme after the first day of vaccination with BNT162b2.
Prompt onset of Rowell's syndrome following the first BNT162b2 SARS‐CoV‐2 vaccination